Premium
Application of network pharmacology and molecular docking to elucidate the potential mechanism of Astragalus–Scorpion against prostate cancer
Author(s) -
Wu Litong,
Chen Ying,
Chen Minjing,
Yang Yueqin,
Che Zuzhao,
Li Qixin,
You Xujun,
Fu Wei
Publication year - 2021
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.14165
Subject(s) - astragalus , active ingredient , computational biology , drugbank , docking (animal) , kegg , biology , pharmacology , chemistry , drug , biochemistry , medicine , traditional chinese medicine , gene ontology , gene , gene expression , alternative medicine , nursing , pathology
The present study aimed to investigate the molecular mechanism of the Astragalus–Scorpion drug pair in the treatment of prostate cancer (PCa). We employed network pharmacology and molecular docking technology to retrieving the active ingredients and corresponding targets of Astragalus–Scorpion by using TCMSP, BATMAN‐TCM, TCMID and Swiss Target Prediction Databases. The targets related to PCa were retrieved through GeneCards. Cytoscape software was used to construct the ‘active ingredient–target disease’ network, and GO and KEGG enrichment analyses were performed on the common targets. Autodock software was used for molecular docking verification. In total, 26 active ingredients, 340 potential targets related to active ingredients and 122 common targets were screened from Astragalus–Scorpion drug pair. The core targets of the protein–protein interaction (PPI) network were JUN , AKT1 , IL6 , MAPK1 and RELA , whereas the core active ingredients were quercetin, kaempferol, formononetin, 7‐o‐methylisomucronulatol and calycosin. Nearly 762 GO entries and 154 pathways were obtained by using the pathway enrichment analysis. Molecular docking results revealed that quercetin and kaempferol bind to AKT1 and formononetin binds to RELA , all of which were found to be stable bounds.